Twist Bioscience stock hits 52-week high at 155.51 USD

Twist Bioscience Corp (TWST) achieved a remarkable milestone, with its stock reaching a 52-week high of $155.51, marking a substantial 565% surge from its 52-week low of $23.30. This surge represents a 1-year change of 450.98% and a year-to-date return of 351%, showcasing the company's robust performance and investor confidence.

However, InvestingPro analysis suggests the stock may be overvalued at current levels due to high volatility. The company, focused on synthetic biology, is currently valued at $9.67 billion, reflecting positive market sentiment towards its strategic initiatives. Twist Bioscience has also partnered with Eli Lilly's TuneLab for antibody characterization data services, further cementing its position in the AI-driven biotech sector.

Despite a sell rating from BWS Financial citing competitive pressures, Guggenheim maintains a Buy rating, underscoring the company's potential in AI-enabled drug discovery. A prospectus supplement filed for the resale of shares to Invenra Inc. also highlights the company's strategic moves. Short seller Scorpion Capital remains skeptical about the AI partnership claims, raising questions about its significance in drug-discovery collaboration.